Nan-Chun Wu1,2, Yin-Hsun Feng3, Yu Hsuan Kuo3, Wei-Yu Chen3, Hong-Chang Wu3, Chien-Tai Huang3, Wen-Ching Wang4, Nai-Wen Kang3, Jhih-Yuan Shih5,6, Zhih-Cherng Chen5, Wei-Ting Chang5,7,8. 1. Division of Cardiovascular Surgery, Department of Surgery, Chi Mei Medical Center. 2. Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy and Science. 3. Division of Oncology, Department of Internal Medicine. 4. Division of General Surgery, Department of Surgery. 5. Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center. 6. Department of Health and Nutrition, Chia Nan University of Pharmacy and Science. 7. Department of Biotechnology, Southern Taiwan University of Science and Technology. 8. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Abstract
BACKGROUND: Despite the increasing prevalence of therapies utilizing immune checkpoint inhibitors (ICIs), the associated cardiovascular complications have been poorly reported. Given the fatality of ICI-related complications, especially myocarditis, optimal risk stratification to predict major adverse cardio- and cerebrovascular events (MACCEs) in patients receiving ICIs is mandatory. METHODS: We collected clinical data from patients receiving ICIs, and the primary outcomes were MACCEs, including myocarditis, heart failure, and ischemic stroke. Other systemic immune responses relating to ICIs were also recorded. The median follow-up duration was 3 years. RESULTS: Among 580 patients, the incidence of MACCEs was 3.9%. Older patients, male patients, and patients with lung cancer, liver cirrhosis, or diabetes had higher risks of MACCEs. There was no significant difference between the use of PD-1/PD-L1 inhibitors or CTLA inhibitors in terms of developing cardiovascular toxicities. The development of ICI-related MACCEs was associated with worse survival. Notably, after re-review by specialists, three patients eventually diagnosed with ICI-related myocarditis had not previously been identified. Only one was treated with pulse steroids, and none survived. The most common concomitant extracardiac immune-related adverse events were myositis/dermatitis, endocrine toxicity and hepatitis. CONCLUSIONS: Collectively, ICIs may lead to severe cardiovascular toxicities and require more attention. Early identification, proper diagnosis, and prompt treatment are pivotal for improving survival.
BACKGROUND: Despite the increasing prevalence of therapies utilizing immune checkpoint inhibitors (ICIs), the associated cardiovascular complications have been poorly reported. Given the fatality of ICI-related complications, especially myocarditis, optimal risk stratification to predict major adverse cardio- and cerebrovascular events (MACCEs) in patients receiving ICIs is mandatory. METHODS: We collected clinical data from patients receiving ICIs, and the primary outcomes were MACCEs, including myocarditis, heart failure, and ischemic stroke. Other systemic immune responses relating to ICIs were also recorded. The median follow-up duration was 3 years. RESULTS: Among 580 patients, the incidence of MACCEs was 3.9%. Older patients, male patients, and patients with lung cancer, liver cirrhosis, or diabetes had higher risks of MACCEs. There was no significant difference between the use of PD-1/PD-L1 inhibitors or CTLA inhibitors in terms of developing cardiovascular toxicities. The development of ICI-related MACCEs was associated with worse survival. Notably, after re-review by specialists, three patients eventually diagnosed with ICI-related myocarditis had not previously been identified. Only one was treated with pulse steroids, and none survived. The most common concomitant extracardiac immune-related adverse events were myositis/dermatitis, endocrine toxicity and hepatitis. CONCLUSIONS: Collectively, ICIs may lead to severe cardiovascular toxicities and require more attention. Early identification, proper diagnosis, and prompt treatment are pivotal for improving survival.
Authors: Dawn O Kleindorfer; Amytis Towfighi; Seemant Chaturvedi; Kevin M Cockroft; Jose Gutierrez; Debbie Lombardi-Hill; Hooman Kamel; Walter N Kernan; Steven J Kittner; Enrique C Leira; Olive Lennon; James F Meschia; Thanh N Nguyen; Peter M Pollak; Pasquale Santangeli; Anjail Z Sharrief; Sidney C Smith; Tanya N Turan; Linda S Williams Journal: Stroke Date: 2021-05-24 Impact factor: 7.914
Authors: Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2020-05-23 Impact factor: 11.527
Authors: Nicolas Palaskas; Juan Lopez-Mattei; Jean Bernard Durand; Cezar Iliescu; Anita Deswal Journal: J Am Heart Assoc Date: 2020-01-21 Impact factor: 5.501